Currency In USD
| Previous Close | 3.7 |
| Open | 3.72 |
| Day High | 3.72 |
| Day Low | 3.67 |
| 52-Week High | 15.74 |
| 52-Week Low | 2.83 |
| Volume | 896,928 |
| Average Volume | 1.6M |
| Market Cap | 280.01M |
| PE | -3.03 |
| EPS | -1.21 |
| Moving Average 50 Days | 3.78 |
| Moving Average 200 Days | 6.7 |
| Change | -0.03 |
Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
GlobeNewswire Inc.
Feb 24, 2026 12:00 PM GMT
― Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12), representing a rapid, robust, and clinically relevant response, with progression toward pan-cellular HbF induction as F-cells increased from 31% to 63%
Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
GlobeNewswire Inc.
Feb 17, 2026 1:00 PM GMT
CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rar
Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 07, 2026 1:00 PM GMT
CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rar